Document Detail


Role of Cell Cycle Biomarkers in Human Papillomavirus Related Uterine Lesions.
MedLine Citation:
PMID:  23016774     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Cervical cancer (CC) is caused by a persistent infection by certain human papillomavirus (HPV) genotypes. Although Papanicolaou (Pap) Test is considered the most cost-effective test for reducing CC mortality a considerable number of high-grade precursor lesions of CC could pass unnoticed with the Pap. The addition of high-risk human papillomavirus (HPV) genotype detection in cervical cytology has improved the sensitivity, but due to its low specificity, further biomarkers of malignancy have been searched for. Given the fact that the oncogenic role of HPV is exerted primary by affecting cell cycle control it is not surprising that most of the useful biomarkers of HPV-related uterine lesions are cell cycle proteins, being p16 and Ki67 the most widely used. More recently, molecular profiling and marker combination tests have identified the utility of antibody cocktails such as p16/Ki67 dual and ProEx C, which detect both TOP2A and MCM2 cell cycle proteins. In this article we revise the rationale for the use of the most common cell cycle biomarkers, also including p53 and cyclin D1, and their clinical utility drawing attention to novel biomarkers and how HPV vaccination could influence their use.
Authors:
Pablo Conesa-Zamora
Related Documents :
2346504 - Influence of a stationary magnetic field on bioelectric properties of snail neurons.
19488724 - Functionalized magnetic nanoparticles as an in vivo delivery system.
12632404 - Levitation and movement of human tumor cells using a printed circuit board device based...
18331184 - Bioimpedance measurements of human body composition: critical analysis and outlook.
1385114 - The human t cell antigen gp39, a member of the tnf gene family, is a ligand for the cd4...
20687544 - Synthesis and in vitro evaluation of defined hpma folate conjugates: influence of aggre...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-24
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
HGUSL. C/Mezquita s/n. 30202, Cartagena, Spain. pablo.conesa@carm.es.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Liquid-Based Cytology with HPV Triage of Low-Grade Cytological Abnormalities versus Conventional Cyt...
Next Document:  Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatme...